About Ascilion
Ascilion is a company based in Stockholm (Sweden) founded in 2012 by Markus Renlund and Pelle Rangsten. It operates as a HealthTech. Ascilion has raised $2.23 million across 3 funding rounds from investors including European Union and Nordstjernan. Ascilion offers products and services including PElsa. Ascilion operates in a competitive market with competitors including Owen Mumford, Flat Medical, Stable Pharma, Retractable Technologies and KORU Medical Systems, among others.
- Headquarter Stockholm, Sweden
- Founders Markus Renlund, Pelle Rangsten
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ascilion Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.23 M (USD)
in 3 rounds
-
Latest Funding Round
$2.23 M (USD), Series A
Sep 22, 2025
-
Investors
European Union
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ascilion
Ascilion offers a comprehensive portfolio of products and services, including PElsa.
Painless sampling of dermal interstitial fluid is enabled.
People of Ascilion
Unlock access to complete
Co Team
1 people
R Team
1 people
Leadership Team
1 people
Product Management Team
1 people
Head Team
1 people
Unlock access to complete
Funding Insights of Ascilion
Ascilion has successfully raised a total of $2.23M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $2.23 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ascilion
Ascilion has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and Nordstjernan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Nordstjernan is operated as a foundation-owned investment house in Sweden.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Ascilion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ascilion
Investment portfolio details for Ascilion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ascilion
Detailed financials for Ascilion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ascilion Comparisons
Peer comparison for Ascilion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ascilion
Ascilion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Owen Mumford, Flat Medical, Stable Pharma, Retractable Technologies and KORU Medical Systems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Disposables for drug delivery and capillary blood sampling are manufactured.
|
|
| Locked | Locked | Locked |
Epidural injection syringes with pressure detection are manufactured.
|
|
| Locked | Locked | Locked |
Developer of technology to store and deliver stable drugs and vaccines
|
|
| Locked | Locked | Locked |
Provides portfolio of smart syringes and needles to prevent from needle-stick injuries
|
|
| Locked | Locked | Locked |
Infusion systems and accessories for subcutaneous drug administration are manufactured.
|
|
| Locked | Locked | Locked |
Manufacturer of silicon microneedle for intradermal injections
|
Detailed competitors of Ascilion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ascilion
Complete news archive for Ascilion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ascilion
Ascilion was founded in 2012 and raised its 1st funding round 9 years after it was founded.
Ascilion is headquartered in Stockholm, Sweden.
Henrik Schwerdt is the current CEO of Ascilion.
Ascilion is a funded company, having raised a total of $2.23M across 3 funding rounds to date.
Ascilion is engaged in the design, development, and manufacturing of products utilizing hollow microneedles for sampling dermal interstitial fluid (dISF). This technology is applied in sectors such as metabolic health monitoring, stress assessment, reproductive hormone tracking, and drug therapy management. Solutions are developed to enable painless and user-friendly access to biomarkers in dISF, supporting next-generation diagnostics and wearable health monitoring devices. Research and clinical trials are conducted to characterize both the system and the fluid itself. Collaborations with industrial partners and researchers worldwide are maintained to advance health science applications.
Ascilion's top competitors include KORU Medical Systems, Stable Pharma and Flat Medical.
Ascilion offers PElsa.
Ascilion has 2 investors. Key investors include European Union, and Nordstjernan.